UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

According to JMP Securities, Oncothyreon ONTY price target is raised to $14. JMP said that near-term catalysts could unlock potential upside; reiterate Market Outperform rating and raising price target to $14 from $8 for Oncothyreon. "We are increasing our sum-of-the-parts driven price target to $14, to reflect higher peak sales projections for Stimuvax and inclusion of pipeline value, now comprising $9 for Stimuvax (previously $8) and $4.50 for PX-866, ONT-10 and cash." Oncothyreon closed yesterday at $6.22.